EP0930891A4 - Oral administration of chicken yolk antibodies to treat disease - Google Patents

Oral administration of chicken yolk antibodies to treat disease

Info

Publication number
EP0930891A4
EP0930891A4 EP97909921A EP97909921A EP0930891A4 EP 0930891 A4 EP0930891 A4 EP 0930891A4 EP 97909921 A EP97909921 A EP 97909921A EP 97909921 A EP97909921 A EP 97909921A EP 0930891 A4 EP0930891 A4 EP 0930891A4
Authority
EP
European Patent Office
Prior art keywords
oral administration
treat disease
yolk antibodies
chicken yolk
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97909921A
Other languages
German (de)
French (fr)
Other versions
EP0930891A1 (en
Inventor
Marilyn A Coleman
Mitchell V Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovimmune Inc
Original Assignee
Ovimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovimmune Inc filed Critical Ovimmune Inc
Publication of EP0930891A1 publication Critical patent/EP0930891A1/en
Publication of EP0930891A4 publication Critical patent/EP0930891A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97909921A 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease Withdrawn EP0930891A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72440896A 1996-10-02 1996-10-02
US724408 1996-10-02
PCT/US1997/017722 WO1998014209A1 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Publications (2)

Publication Number Publication Date
EP0930891A1 EP0930891A1 (en) 1999-07-28
EP0930891A4 true EP0930891A4 (en) 2001-07-04

Family

ID=24910322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97909921A Withdrawn EP0930891A4 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Country Status (7)

Country Link
EP (1) EP0930891A4 (en)
JP (1) JP2001501622A (en)
KR (1) KR20000048855A (en)
AU (1) AU729502B2 (en)
CA (1) CA2267421A1 (en)
NZ (1) NZ335170A (en)
WO (1) WO1998014209A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
DE19910159A1 (en) * 1999-02-26 2000-09-14 Rosemarie Heis Specific IgY egg yolk antibodies, their extraction and their use
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
EP1246848A1 (en) 1999-12-27 2002-10-09 University Of Manitoba GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS
KR100364198B1 (en) * 2000-06-09 2002-12-12 영농조합법인다한 An Improved Method for Inducing IgY to Helicobacter pylori and an Egg Prepared by Using the Same
CA2437099A1 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
EP1357943A2 (en) * 2001-01-30 2003-11-05 The Lauridsen Group Incorporated Methods and compositions for modulating the immune system of animals
CA2339436A1 (en) 2001-03-15 2002-09-15 Josee Harel Production of antibodies against virulence factors associated with strains of escherichia coli (aeec), and their use
KR20030026502A (en) * 2001-09-26 2003-04-03 배만종 A production method of common egg, native egg, blue egg have various skill
KR100392566B1 (en) * 2001-11-13 2003-07-23 주식회사 에그 바이오택 THE PRODUCTION METHOD OF EGG CONTAINING MIXING IgY ABOUT Propionibacterium acnes, Staphylococcus epidermidis, E.coli CAUSING ACNES AND THEREOF PREVENTING COSMETICS FOR ACNES SKIN CONTAINING MIXING IgY
JP2006504393A (en) * 2001-12-28 2006-02-09 カマス インコーポレイテッド Immune antigen adhesion agent and method for producing and using the same
KR100489615B1 (en) * 2002-01-30 2005-05-17 주식회사 단바이오텍 Antibody For Prevention And Treatment Of Listeria Monocytogenes Infection, Eggs Containing Thereof And Method For Producing Thereof
KR20030079382A (en) * 2002-04-04 2003-10-10 최태부 An antibody induced by digestive enzyme-fatty acid complex and use thereof
AU2002313212A1 (en) * 2002-06-13 2003-12-31 Kabushiki Gaisha Tokaibiken Tailor-made preparation and process for producing the same
KR20040005540A (en) * 2002-07-10 2004-01-16 백반석 The method for production of specific yolk antibody containing anti-helicobacter pylori IgY,anti-helicobacter pylori enzyme(urease, proteases, lipase, phosph olipase)IgY,anti-E.coli(EHEC),anti-salmonella enteritidis IgY,anti-staphylococcus aureus IgY.
KR20040005539A (en) * 2002-07-10 2004-01-16 백반석 The method for separation and production of water-soluble specific protein(IgY) using electrolytic water and saccharide
KR20040005541A (en) * 2002-07-10 2004-01-16 선우선영 The effective producing method of anti-acnes IgYs in several form.
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
CA2561800C (en) * 2004-04-16 2011-10-18 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
EP1723951A1 (en) * 2005-04-21 2006-11-22 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
JP2007084495A (en) * 2005-09-22 2007-04-05 Daikin Ind Ltd Method for treating virus-infected cell
JP2007082486A (en) * 2005-09-22 2007-04-05 Daikin Ind Ltd Method for treating biologic material infected with virus, cell treated against infection virus, tissue treated against infection virus, organ treated against infection virus
AU2007291891B2 (en) * 2006-08-31 2013-10-31 A.C.N. 135 493 391 Pty Ltd Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
ES2573636T3 (en) 2006-10-25 2016-06-09 Wisconsin Alumni Research Foundation Methods to reduce phosphate absorption using an anti-Npt2B antibody
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
EA034057B1 (en) 2010-11-23 2019-12-23 Пантерикс, Инк. Method of reducing duration of diarrhea caused by enteric infection
US20130011410A1 (en) * 2011-07-07 2013-01-10 Amicus Biotech Inc. Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule
AU2012298125B2 (en) 2011-08-19 2015-09-24 Immortal Spirit Limited Antibody and antibody-containing composition
CN106749650B (en) * 2016-12-19 2021-06-25 姚善龙 Preparation method and application of composite IgY antibody for resisting cold virus, streptococcus pneumoniae and staphylococcus
KR102200721B1 (en) * 2019-11-18 2021-01-13 (주)애드바이오텍 Manufacturing method of immunoglobulin y for preventing or treating salmon rickettisia septicaemia
CN112957464A (en) * 2021-02-24 2021-06-15 江秀坤 Application of chicken egg yolk immunoglobulin in preparing throat-moistening health-care product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19504755A1 (en) * 1995-02-02 1996-08-08 Panagiotis Tsolkas New antibodies against HIV antigens
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE19504755A1 (en) * 1995-02-02 1996-08-08 Panagiotis Tsolkas New antibodies against HIV antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERTEL R ET AL: "Formation of antibodies to prostaglandins in the yolk of chicken eggs.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1981 OCT 15) 102 (3) 1028-33., XP000984898 *
See also references of WO9814209A1 *

Also Published As

Publication number Publication date
KR20000048855A (en) 2000-07-25
CA2267421A1 (en) 1998-04-09
JP2001501622A (en) 2001-02-06
AU4741997A (en) 1998-04-24
AU729502B2 (en) 2001-02-01
NZ335170A (en) 2001-08-31
EP0930891A1 (en) 1999-07-28
WO1998014209A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
EP0930891A4 (en) Oral administration of chicken yolk antibodies to treat disease
GB9401520D0 (en) Treatment of poultry
IL121894A (en) Process for the preparation of a protein composition from animal muscle tissue
PL335974A1 (en) Method of orally administering proteins
NO995134L (en) Improved Methods for Preparation of Activated Protein C
GR3036315T3 (en) Indolinone compounds for the treatment of disease
EP0979647A4 (en) Fat emulsion for oral administration
ZA931489B (en) Use of interleuken-10 to suppress graft-vs-host disease
AU2340397A (en) Use of nicotine to treat liver disease
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
TR199701051A3 (en) Preparation process of 2 '-Fluoro-5-methyl--1-arabino-furanosyluridine
PL337064A1 (en) Method of and compositions for orally administering taxanes to human beings
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL117668A0 (en) Preparation of polyesters
IL115307A (en) Modification of egg composition by chicken feed supplements and the resulting eggs obtained
ZA969147B (en) Application of the gax protein to the treatment of cancer
PL326080A1 (en) Short forms of chemokin beta-8
GB9801142D0 (en) Administration of beneficial substances to ruminant animals
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
AU7492087A (en) Newcastle disease virus protein
EP0755262A4 (en) Composition for the treatment of lung disease
IL119282A0 (en) Treatment of fowl
AU7712598A (en) Lipid-reduced oral formulation for egg yolk-derived therapeutic protein
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
IL114923A0 (en) Chintin extract for treatment of skin disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503